Moberg Pharma: Exciting year ahead
Research Update
2023-02-08
07:01
Redeye sees a Q4 report that was uneventful as expected. The highlight for the year is the expected EU regulatory approval during 2023e. The long-term outlook for MOB-015 still looks bright. We see that Moberg Pharma is progressing as planned, and the EU approval during 2023 should be an important catalyst as we advance.
MH
Mats Hyttinge
Disclosures and disclaimers